Compugen Ltd. (NASDAQ:CGEN – Get Rating) was the recipient of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 4,120,000 shares, a drop of 16.4% from the May 15th total of 4,930,000 shares. Based on an average daily volume of 918,500 shares, the days-to-cover ratio is currently 4.5 days. Approximately 5.5% of the company’s stock are short sold.
Several institutional investors have recently made changes to their positions in the stock. Invesco Ltd. purchased a new stake in shares of Compugen in the second quarter valued at about $92,000. Virtu Financial LLC bought a new stake in Compugen during the 1st quarter valued at $37,000. Oppenheimer & Co. Inc. bought a new stake in Compugen in the fourth quarter valued at $49,000. Walleye Trading LLC bought a new position in shares of Compugen in the 4th quarter worth about $55,000. Finally, Barclays PLC raised its position in shares of Compugen by 58.8% in the 3rd quarter. Barclays PLC now owns 13,562 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 5,024 shares during the last quarter.
Shares of NASDAQ:CGEN opened at $1.68 on Friday. Compugen has a 52 week low of $1.55 and a 52 week high of $9.20. The firm’s 50 day moving average is $2.10 and its two-hundred day moving average is $3.09. The firm has a market capitalization of $114.95 million, a P/E ratio of -4.31 and a beta of 2.43.
A number of research analysts have issued reports on CGEN shares. Oppenheimer decreased their target price on Compugen from $17.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, February 25th. StockNews.com upgraded Compugen from a “sell” rating to a “hold” rating in a report on Monday, May 30th. Finally, SVB Leerink cut their price objective on Compugen from $16.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, February 25th.
Compugen Company Profile (Get Rating)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Compugen (CGEN)
- The Analysts Upgrade… Retail Stocks?
- Dividend Stocks and Your Roth IRA
- The Q2 Earnings Season Could Be A Bloodbath
- Commercial Metals Company Is Ready To Rebound
- The Institutions Turn The Tide For Jabil
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.